CJC-1295 and ipamorelin blends

CJC-1295 is a GHRH analogue; ipamorelin acts at the ghrelin receptor. The rationale offered for combining them is that they approach pituitary signalling from two different directions, and that doing both is more effective than doing either.

BPC-157 with TB-500 follows a different rationale: two compounds discussed in preclinical recovery research, paired on the theory that their mechanisms are complementary.

Both rationales are mechanistically coherent stories. Neither is the same thing as evidence that the combination does anything useful in a person.

For a combination to be assessed properly you would want human data on each component and then on the combination. In this category you generally have neither.

• If something goes wrong, you cannot attribute it to one component or the other.
• If nothing happens, you cannot tell which component failed or whether either was in the vial.
• Interaction effects between two unapproved compounds have not been characterised in people.
• Blended preparations make the sourcing question harder, because now the identity and purity of two substances are in question rather than one.

All four fall under the WADA prohibited list for this class.

This is the most searched pairing in the category and it deserves separating from the question of choosing between the two. Comparing them is a decision about which one; stacking them is a decision to use both, and the two questions have different answers.

The rationale offered is that the two act through different mechanisms — one associated with a gastric protein fragment, the other related to actin regulation — and therefore complement each other in recovery contexts. As a mechanistic story it is coherent. As evidence it is not: neither compound has substantial human trial evidence individually, so a claim about the pair rests on two unestablished foundations rather than one.

FDA has stated a specific concern for each. For BPC-157 it cites potential immunogenicity for certain routes, complexity in characterising the ingredient and its peptide-related impurities, and no or only limited safety information for the proposed routes. For thymosin beta-4 fragment it cites potential immunogenicity from aggregation and peptide-related impurities, and states it has not identified any human exposure data at all.

Both were considered at the same Pharmacy Compounding Advisory Committee meeting on 23-24 July 2026 for possible inclusion on the 503A Bulks List — BPC-157 reviewed for ulcerative colitis, TB-500 for wound healing. That meeting has taken place and neither substance's legal position moved: advisory recommendations are non-binding, the list is amended only through notice-and-comment rulemaking, and neither appears on it as fetched on 2026-08-23. What the vote did and did not do is set out on the peptide legal-status page.

The practical point: a supplier offering the pair as a package should be able to account for each component separately, because the regulator does.

Ask which pharmacy prepares it and under what authority for each component. Ask what testing the finished preparation goes through. Ask what is being measured before and during, and what result would cause the clinician to stop.

Dosing is determined by a licensed provider.

How we verify providers

• FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — retrieved 2026-08-06
• FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — retrieved 2026-08-06
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — retrieved 2026-08-06
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — retrieved 2026-08-23
• WADA — The Prohibited List — retrieved 2026-08-13